Form 4: Atlas Venture Exits VIGL Stake in Sanofi Merger

Atlas Venture entities disposed of their shares in Vigil Neuroscience, Inc. as part of its merger with Sanofi, receiving $8.00 cash plus a $2.00 contingent value right per share.

Summary

• Atlas Venture Fund XII, L.P. and related entities, acting as 10% owners and directors, reported the disposition of their beneficial ownership in Vigil Neuroscience, Inc. (VIGL).
• The transaction occurred on August 5, 2025, as a result of Vigil Neuroscience, Inc. merging with Vesper Acquisition Sub Inc., a wholly owned subsidiary of Sanofi.
• Following the merger, Vigil Neuroscience, Inc. continues as the surviving corporation and is now a wholly owned subsidiary of Sanofi.
• Each outstanding share of Vigil Neuroscience Common Stock was converted into the right to receive $8.00 in cash and one contingent value right (CVR) for an additional $2.00 in cash, conditioned upon the satisfaction of a specific clinical milestone.
• Atlas Venture Fund XII, L.P. directly disposed of 4,808,896 shares of Common Stock.
• Atlas Venture Opportunity Fund I, L.P. indirectly disposed of 1,027,978 shares of Common Stock.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing a defined exit for shareholders at a premium, with potential for additional value via a CVR. This indicates a positive outcome for the reporting entities and VIGL shareholders.

Positives

• The merger provides a clear and defined exit strategy for shareholders, including Atlas Venture, at a specified cash value.
• The contingent value right (CVR) offers potential additional upside of $2.00 per share upon the achievement of a clinical milestone.

Negatives

• Vigil Neuroscience, Inc. ceases to be an independent publicly traded company.
• The full $10.00 per share consideration is not guaranteed, as the $2.00 CVR is contingent on a future clinical milestone.

Risks

• The primary risk is that the contingent value right (CVR) of $2.00 per share is not guaranteed and is dependent on the satisfaction of a specific clinical milestone.

Future Outlook

Vigil Neuroscience, Inc. is now a wholly-owned subsidiary of Sanofi, and its future operations will be integrated within Sanofi. The future value for CVR holders depends entirely on the achievement of the specified clinical milestone.

Industry Context

This transaction is characteristic of the biotechnology and pharmaceutical industry, where larger pharmaceutical companies often acquire smaller biotech firms to gain access to promising pipelines and intellectual property. The use of a contingent value right is a common mechanism to bridge valuation gaps and share future development risks.

Comparison to Industry Standards

• The filing does not provide specific details on the clinical milestone or the overall valuation metrics of Vigil Neuroscience, Inc. prior to the merger, which would be necessary for a detailed comparison to industry-specific acquisition benchmarks.
• The structure of an upfront cash payment combined with a contingent value right is a standard approach in biotech M&A, particularly when there is significant clinical development risk or future value tied to specific pipeline assets.

Related Party Transactions

• The reporting persons (Atlas Venture Fund XII, L.P. and related entities) were 10% owners and directors of Vigil Neuroscience, Inc., making their disposition of shares as part of the merger a transaction involving a significant related party.

Stakeholder Impact

• Shareholders of Vigil Neuroscience, Inc. received a cash payment and a contingent value right, providing liquidity and potential future upside.
• Employees of Vigil Neuroscience, Inc. will be integrated into Sanofi's organizational structure.
• Sanofi has expanded its pipeline and capabilities by acquiring Vigil Neuroscience, Inc.'s assets.

Next Steps

• For holders of the contingent value rights, monitoring the progress and achievement of the specified clinical milestone will be the next key event.
• Vigil Neuroscience, Inc. will undergo integration into Sanofi's operations.

Key Dates

Recommendation

The filing details the completion of a merger where Vigil Neuroscience, Inc. was acquired by Sanofi. As such, the common stock of Vigil Neuroscience, Inc. is no longer publicly traded, making traditional buy/sell recommendations irrelevant. For holders of the contingent value rights (CVRs), the recommendation is to hold as their value is tied to a future clinical milestone.

Keywords

SEC Form 4, Merger, Acquisition, Vigil Neuroscience, VIGL, Sanofi, Atlas Venture, Contingent Value Right, CVR, Beneficial Ownership, Biotechnology, Pharmaceutical